RCT | Comparing exemestane dose regimens in early-stage ER+ breast cancer

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer – The ASCO Post

Commentary on Twitter

Exemestane 25 mg (Exe) 3x/week (TIW) in compliant patients is comparable to daily dosing in reducing circulating estradiol; a weekly dose was less effective. Toxicity similar in all arms, suggesting Exe TIW may be used in breast cancer prevention. https://t.co/2NugINVrim #BCS

— JAMA Oncology (@JAMAOnc) March 23, 2023